Charlie Chan
Analyst
Baird
Equibles does not estimate personal net worth.
About Charlie Chan
Charlie Chan is recorded as Analyst at Baird. Charlie Chan has spoken on 3 earnings calls across 3 companies, most recently for Jazz Pharmaceuticals plc on May 5, 2026. Those appearances were for Jazz Pharmaceuticals plc (JAZZ), Axsome Therapeutics, Inc. (AXSM) and Gilead Sciences, Inc. (GILD). The companies whose calls Charlie Chan spoke on are classified in the Healthcare sector.
Charlie Chan on recent calls
“I was just wondering if you could give us a sense of the size of the opportunity for Epidiolex in the adult and long-term care setting and maybe some more color on the initiatives you're taking there with the new formulation, as well as would be curious to hear, will you be sharing any data from the phase 1b and focal…”
“So just kind of following up on an earlier question, curious how you're thinking about positioning Synose ahead of potential Rex and Agonist launch later this year, as well as with your expansion of the Salesforce there and wrapping up the expansion of the Ovelity Salesforce, how should we think about kind of the ramp…”
“So again, to ask something about Cell Adelpar, just wondering if you have any ambitions for potentially looking at a label for first line in the future, considering there's a lot of unmet need with pruritus there, as well as any potential synergies you may be considering with the remainder of your liver portfolio.”
Affiliation history
-
Baird
Analyst
Transcript header (unverified)
Current
Company network
Drug Manufacturers - General · Healthcare
1 appearance
Latest appearance 2024-04-25
View calls and events